Classical and novel molecular prognostic factors in ovarian cancers;Klasyczne i nowe molekularne czynniki prognostyczne w rakach jajnika

Polski Merkuriusz Lekarski

Volumn 19, Issue 114, 2005, Pages 823-827

  Zasławski, Ryszard ^a   Surowiak, Paweł ^a,b   Zabel, Maciej ^b,c  

^a Szpital Wojewódzki ^*  (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

CD24; CD46; COX 2; DNA microarray; Ovarian cancer; P53

Indexed keywords

BRCA1 PROTEIN; CA 125 ANTIGEN; CD24 ANTIGEN; CD59 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLOOXYGENASE 2; DECAY ACCELERATING FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FRAGILE HISTIDINE TRIAD PROTEIN; K RAS PROTEIN; LIGAND; MEMBRANE COFACTOR PROTEIN; MYC PROTEIN; ONCOPROTEIN; PADGEM PROTEIN; PROTEIN KINASE B BETA; PROTEIN P53; PROTEIN RB1; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

C FMS GENE; CANCER SUSCEPTIBILITY; DNA MICROARRAY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; ONCOGENE; OVARY CANCER; OVCA1 I2 GENE; PATHOGENESIS; PROGNOSIS; PROTEIN EXPRESSION; RELIABILITY; REVIEW; TUMOR SUPPRESSOR GENE;

ANTIGENS, CD24; ANTIGENS, CD46; CYCLOOXYGENASE 2; FEMALE; GENES, P53; HUMANS; MEMBRANE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 30644464599     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Adib T.R., Henderson S., Perrett C. i wsp: Predicting biomarkers for ovarian cancer using gene-expression microarrays. Brit. J. Cancer, 2004, 90, 686-692.
2. Aigner S., Sthoeger Z.M., Fogel M. i wsp.: CD24, a mucin-type glycoprotein, is a ligand for P-selctin on human tumor cells. Blood, 1997, 89, 3385-3395.
3. Bast R.C. Jr., Klug T.L., St. John E. i wsp.: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med., 1983, 309, 883-887.
4. Bjorge L., Hakulinen J., Wahlstrom T. i wsp.: Complement-regulatory proteins in ovarian malignancies. Int. J. Cancer. 1997, 70, 14-25.
5. De Potter C.: The neu oncogene: more than a prognostic indicator? Hum. Pathol., 1994, 25, 1264-1268.
6. Denkert C., Furstenberg A., Daniel P.T. i wsp.: Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene, 2003, 22, 8653-61.
7. Denkert C., Kobel M., Berger S. i wsp.: Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res., 2001, 61, 303-8.
8. Denkert C., Kobel M., Pest S. i wsp.: Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am. J. Pathol., 2002, 160, 893-903.
9. Denkert C., Winzer K.J., Muller B.M. i wsp.: Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer, 2003, 97, 2978-87.
10. Elder D.: Apoptosis in the prevention of colorectal cancer by non-steroidal anti-inflammatory drugs. Apoptosis, 1999, 4, 365-372.
11. Ferrendina G., Fagotii A., Salerno M.G. i wsp.: p53 overexpression is associated to chemotherapy in ovarian cancer. Br. J. Cancer. 1999, 81, 733-740.
12. Fishelon Z., Donin N., Zell S. i wsp.: Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol., 2003, 40, 109-123.
13. Gasparini G., Longo R., Sarmiento R. i wsp.: Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol., 2003, 4, 605-615.
14. Havrilesky L., Darcy K.M., Hamdan H. i wsp.: Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: A Gynecologic Oncology Group Study. J. Clin. Oncol., 2003, 21, 3814-3825.
15. Holschneider C., Berek J.: Ovarian cancer: epidemiology, biology, and prognostic factors. Seminars Surgical Oncol., 2000, 19, 3-10.
16. Kristiansen G., Denkert C., Scluens K. i wsp.: CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am. J. Pathol., 2002, 161, 1215-1221.
17. Kupryjanczyk J., Bell D., Dimeo D.: p53 gene analysis of ovarian bordeline tumors and stage I carcinomas. Hum. Pathol., 1995, 26, 387-392.
18. Niloff J., Klug T., Schaetzl E.: CA 125 antigen levels in obsterics and gynecologic patients. Obstet Gynecol., 1984, 64, 703-706.
19. Niloff J., Klug T.L., Schaetzl E. i wsp.: Elevation of serum CA 125 in carcinomas of the fallopian tube, endometrium and endocervix. Am. J. Obstet. Gynecol., 1984, 148, 1057-1058.
20. Patel V., Dunn M., Sorokin A.: Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J. Biol. Chem., 2002, 227, 38915-38920.
21. Rak jajnika (Markowska J. red.). Springer PWN, Warszawa 1997.
22. Schaner M.E., Ross D.T., Ciaravino G. i wsp.: Gene expression patterns in ovarian carcinoma. Mol. Biol. Cell., 2003, 14, 4376-4386.
23. Schindelmann S., Windisch J., Grundmann R. i wsp.: Expression profiling of mammary carcinoma cell lines: correlation of in vitro invasivenes with expression of CD24. Tumor Biol., 2002, 23, 139-145.
24. Schuijer M., Berns E.: TP53 and ovarian cancer. Human Mut., 2003, 21, 285-291.
25. Siddik Z.: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 2003, 22, 7265-7279.
26. Slamon D., Clark G.: Amplification of C-ERB-B2 and agressive breast tumors? Science, 1988, 240, 1795-1798.
27. Vergote I., Bormer O., Abeler V.: Evaluation of serum CA 125 levels in the monitoring of ovarian cancer. Gynecol. Oncol., 1986, 157, 88-92.
28. Verkis A., Meynard D., Haaz M. C. i wsp.: Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res., 2004, 64, 356-362.
29. Vogelstein B., Lane D., Levine A.: Surfing the p53 network. Nature, 2000, 408, 307-310.
30. Warner T., Mitchel J.: Cyclooxygenases: new forms, new inhibitors, and lesson from the clinic. FASEB J. 2004, 18, 790-804.